Sensorion (ALSEN) H1 2025 earnings summary

Executive summary

• Advanced gene therapy and small molecule programs for hearing loss, with SENS-501 and GJB2-GT progressing in clinical development and SENS-401 advancing in multiple indications.

• SENS-501 (OTOF-GT) Audiogene trial completed enrollment in first two cohorts, showing positive early efficacy and safety data in infants and all six patients treated.

• Early hearing improvement observed in Patient 3 at minimally effective dose; higher dose data from Cohort 2 being gathered, with Data Monitoring Committee review expected by end of H2 2025.

• SENS-401 Phase 2a NOTOXIS trial for Cisplatin-Induced Ototoxicity completed enrollment, with topline data expected by end of H2 2025.

• Leadership strengthened with appointment of Amit Munshi as Chairman and expanded scientific communications.

Financial highlights

• Operating income for H1 2025 was €2.3 million, down from €3.3 million in H1 2024.

• Operating loss widened to €16.8 million from €15.1 million year-over-year.

• Net loss for H1 2025 was €16.0 million, compared to €13.9 million in H1 2024.

• Cash and cash equivalents at June 30, 2025 were €46.6 million, with cash and short-term deposits totaling €57.1 million, down from €66.8 million and €77.0 million at year-end 2024, respectively.

• Total equity decreased to €57.0 million from €72.1 million at December 31, 2024.

Outlook and guidance

• Sufficient liquidity to fund operations into Q3 2026, with no expected liquidity risk in the next 12 months.

• Key milestones: SENS-501 Data Monitoring Committee review and SENS-401 topline results in H2 2025; GJB2-GT clinical trial application in Q1 2026.